17-ethynylandrostane-3,17-diol

11/01/2009 - "HE3235 inhibits growth of castration-resistant prostate cancer."
02/01/2012 - "17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3β-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer. "

01/01/2011 - "These data warrant clinical investigation of HE3235 for breast cancer treatment."
02/01/2012 - "17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235, Apoptone) is an orally bioavailable synthetic analogue of 3β-androstanediol, that is active in rodent models of prostate and breast cancer, and is in Phase IIa clinical trials for the treatment of early- and late-stage prostate cancer. "

11/01/2009 - "HE3235 inhibited tumor growth in the bone environment. "
11/01/2009 - "To investigate the effect of HE3235 on CaP tumor in the bone, castrated mice were injected intratibially with C4-2B CaP cells and treated with HE3235. "
01/01/2011 - "Only HE3235 or HE3235 plus docetaxel continued to suppress tumor growth after cessation of treatment. "
01/01/2011 - "Treatment with HE3235 alone rapidly reduced tumor burden, similar in effect to tamoxifen and anastrozole. "
11/01/2009 - "HE3235 significantly prolonged the tumor doubling time of LuCaP35V, decreased androgen receptor expression, and lowered levels of intratumoral testosterone by approximately 89% and dihydrotestosterone by approximately 63% in both the presence and the absence of AED. "